Trial · NCT01308749
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Could Tolerate Twice Daily Oxytocin | Week 0 to week 8 | This is over period 1, the double blind phase (week 0 to week 8) only | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Could Tolerate Twice Daily Oxytocin | Week 0 to week 16 | all participants who recieved oxytocin at any time | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Mean Plasma Oxytocin Level During Period 1 - Double Blind Phase | Week 0 to week 8 | participants with oxytocin plasma levels at baseline and week 8 | picograms/mL (pg/mL) | MEAN |
| SECONDARY | Change in Mean Weight | between weeks 0 and 8 | The subject who discontinued after 2 days did not have repeat assessments and is excluded from these analyses | pounds | MEAN |
| SECONDARY | Change in Mean Total Social Social Responsiveness Scale (SRS) T-score | 0-8 weeks, blinded treatment, period 1 | All participants with at least one post baseline assessment, 1 person from sequence 1 discontinued due to no post baseline measures | T-scores | MEAN |
| SECONDARY | Change in Mean Autism Diagnostic Observation Schedule (ADOS) Total Score | Baseline to 16 Weeks | 1 patient without post baseline measures is not included | scores on a scale | MEAN |
| SECONDARY | Change in Mean Aberrant Behavior Checklist (ABC)-Social Withdrawal Subscale Score Over Both Periods | Baseline to 16 Weeks | population of participants with all data available for mixed models analysis no data carried forward | scores on a scale | MEAN |
| SECONDARY | Change in Mean Pervasive Developmental Disorder Behavior Inventory - Screening Version (PDDBI-SV) Total Score Over Both Periods | Baseline to 16 Weeks | used only subjects with all data points no data carried forward | scores on a scale | MEAN |
| SECONDARY | Change in Mean Systolic Blood Pressure During Period 1 | Week 0 to 8 | The one subject who discontinued at week 1 did not have follow up data to include in the analysis. | millimeters of mercury (mmHg) | MEAN |
| SECONDARY | Mean Change in Prolactin Levels Over Period 1 | Week 0 to 8 | nanograms per milliliter (ng/mL) | MEAN | |
| SECONDARY | Mean Change in Temperature During Period 1 | Week 0 to 8 | degrees fahrenheit | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01308749/outcomes